RAM
ADCT icon

Readystate Asset Management’s ADC Therapeutics ADCT Stock Holding History

Readystate Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,620
Closed -$31.1K – 593
2024
Q4 		$31.1K Sell
15,620
-1,419
-8% -$3.71K ﹤0.01% 599
2024
Q3 		$53.7K Buy
+17,039
New +$53.7K ﹤0.01% 518

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Readystate Asset Management's ADCT Position: Q1 2025 in Review

Readystate Asset Management sold out of ADC Therapeutics (ADCT) in Q1 2025, closing a stake of 15,620 shares — an estimated $31.1K sold.

Readystate Asset Management first reported a position in ADCT in Q3 2024 and held it in 2 quarters. The position peaked at $53.7K in Q3 2024. 82 funds tracked by Wall St. Rank hold ADCT as of Q1 2025.

  • Readystate Asset Management reported no remaining ADC Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Readystate Asset Management sold 15,620 ADC Therapeutics shares in Q1 2025, an estimated $31.1K.
  • Readystate Asset Management first reported a position in ADC Therapeutics in Q3 2024 and held it in 2 quarters.
  • Readystate Asset Management's ADC Therapeutics position peaked at $53.7K in Q3 2024.
  • 82 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.